Trading in Theravance Common Stock Halted

Trading in Theravance Common Stock Halted 
FDA Advisory Committee to Review BREO(TM) ELLIPTA(TM) NDA 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/17/13 --  Theravance,
Inc. (NASDAQ: THRX) today announced that NASDAQ halted trading of
Theravance common stock this morning, April 17, 2013. The
Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug
Administration (FDA) meets today to discuss the new drug application
(NDA) 204275, for fluticasone furoate (FF) and vilanterol (VI) dry
powder inhaler (proposed trade name BREO(TM) ELLIPTA(TM)), sponsored
by GlaxoSmithKline plc (GSK), for the long-term maintenance treatment
of airflow obstruction and for reducing exacerbations in patients
with chronic obstructive pulmonary disease. FF/VI, an investigational
once-daily inhaled corticosteroid/long-acting beta2 agonist (LABA)
combination treatment, is in development under the LABA collaboration
between GSK and Theravance, Inc. 
About Theravance 
Theravance is a biopharmaceutical company with a pipeline of
internally discovered product candidates and strategic collaborations
with pharmaceutical companies. Theravance is focused on the
discovery, development and commercialization of small molecule
medicines across a number of therapeutic areas including respiratory
disease, bacterial infections, and central nervous system (CNS)/pain.
Theravance's key programs include: RELVAR(TM) or BREO(TM) ELLIPTA(TM)
(FF/VI), ANORO(TM) ELLIPTA(TM) (UMEC/VI) and MABA (Bifunctional
Muscarinic Antagonist-Beta2 Agonist), each partnered with
GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor
Antagonist program. By leveraging its proprietary insight of
multivalency to drug discovery, Theravance is pursuing a
best-in-class strategy designed to discover superior medicines in
areas of significant unmet medical need. For more information, please
visit Theravance's web site at 
THERAVANCE(R), the Theravance logo, and MEDICINES THAT MAKE A
DIFFERENCE(R) are registered trademarks of Theravance, Inc.  
(UMEC/VI) are investigational medicines and are not currently
approved anywhere in the world. RELVAR(TM), BREO(TM), ANORO(TM) and
ELLIPTA(TM) are trademarks of the GlaxoSmithKline group of companies.
The use of these brand names has not yet been approved by any
regulatory authority. 
Contact Information: 
Michael W. Aguiar
Senior Vice President and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.